These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Comstock TL; Paterno MR; Decory HH; Usner DW Clin Drug Investig; 2010; 30(10):675-85. PubMed ID: 20629472 [TBL] [Abstract][Full Text] [Related]
25. Eye drops and eye gels of levofloxacin: comparison of ocular absorption characterizations and therapeutic effects in the treatment of bacterial keratitis in rabbits. Li G; Xu L; Jiang M; Wu X Drug Dev Ind Pharm; 2020 Apr; 46(4):673-681. PubMed ID: 32233932 [TBL] [Abstract][Full Text] [Related]
26. Postantibiotic effects and bactericidal activities of levofloxacin and gatifloxacin at concentrations simulating those of topical ophthalmic administration against fluoroquinolone-resistant and fluoroquinolone-sensitive methicillin-resistant Staphylococcus aureus strains. Hoshi S; Kikuchi K; Sasaki T; Sotozono C; Kinoshita S; Hiramatsu K Antimicrob Agents Chemother; 2008 Aug; 52(8):2970-3. PubMed ID: 18490505 [TBL] [Abstract][Full Text] [Related]
27. Use of Topical Besifloxacin in the Treatment of Mycobacterium chelonae Ocular Surface Infections. Nguyen AT; Hong AR; Baqai J; Lubniewski AJ; Huang AJ Cornea; 2015 Aug; 34(8):967-71. PubMed ID: 26075451 [TBL] [Abstract][Full Text] [Related]
29. Efficacy of gemifloxacin for the treatment of experimental Staphylococcus aureus keratitis. Wu X; Jiang H; Xu Y; Yue W; Yang L; Song Z; Chen H; Liu T J Ocul Pharmacol Ther; 2012 Aug; 28(4):420-7. PubMed ID: 22360669 [TBL] [Abstract][Full Text] [Related]
30. Besifloxacin in the management of bacterial infections of the ocular surface. Deschênes J; Blondeau J Can J Ophthalmol; 2015 Jun; 50(3):184-91. PubMed ID: 26040217 [TBL] [Abstract][Full Text] [Related]
31. New Approach in Ocular Drug Delivery: In vitro and ex vivo Investigation of Cyclodextrin-Containing, Mucoadhesive Eye Drop Formulations. Bíró T; Bocsik A; Jurišić Dukovski B; Gróf I; Lovrić J; Csóka I; Deli MA; Aigner Z Drug Des Devel Ther; 2021; 15():351-360. PubMed ID: 33568896 [TBL] [Abstract][Full Text] [Related]
32. Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial keratitis: a retrospective safety surveillance study. Schechter BA; Parekh JG; Trattler W J Ocul Pharmacol Ther; 2015 Mar; 31(2):114-21. PubMed ID: 25409447 [TBL] [Abstract][Full Text] [Related]
33. Besifloxacin-loaded ocular nanoemulsions: design, formulation and efficacy evaluation. Kassaee SN; Mahboobian MM Drug Deliv Transl Res; 2022 Jan; 12(1):229-239. PubMed ID: 33575973 [TBL] [Abstract][Full Text] [Related]
34. Enhancing and sustaining the topical ocular delivery of fluconazole using chitosan solution and poloxamer/chitosan in situ forming gel. Gratieri T; Gelfuso GM; de Freitas O; Rocha EM; Lopez RF Eur J Pharm Biopharm; 2011 Oct; 79(2):320-7. PubMed ID: 21641994 [TBL] [Abstract][Full Text] [Related]
35. Anti-inflammatory effects of besifloxacin, a novel fluoroquinolone, in primary human corneal epithelial cells. Zhang JZ; Cavet ME; Ward KW Curr Eye Res; 2008 Nov; 33(11):923-32. PubMed ID: 19085374 [TBL] [Abstract][Full Text] [Related]
36. Levofloxacin Hemihydrate In Situ Gelling Ophthalmic Solution: Formulation Optimization and In Vitro and In Vivo Evaluation. Bhalerao H; Koteshwara KB; Chandran S AAPS PharmSciTech; 2019 Aug; 20(7):272. PubMed ID: 31372767 [TBL] [Abstract][Full Text] [Related]
37. Therapeutic Effectiveness in the Treatment of Experimental Bacterial Keratitis with Ion-activated Mucoadhesive Hydrogel. Kesavan K; Kant S; Pandit JK Ocul Immunol Inflamm; 2016 Oct; 24(5):489-92. PubMed ID: 26133969 [TBL] [Abstract][Full Text] [Related]
38. Application of Box-Behnken design for preparation of levofloxacin-loaded stearic acid solid lipid nanoparticles for ocular delivery: Optimization, in vitro release, ocular tolerance, and antibacterial activity. Baig MS; Ahad A; Aslam M; Imam SS; Aqil M; Ali A Int J Biol Macromol; 2016 Apr; 85():258-70. PubMed ID: 26740466 [TBL] [Abstract][Full Text] [Related]
39. Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci. Miller D; Chang JS; Flynn HW; Alfonso EC J Ocul Pharmacol Ther; 2013 Apr; 29(3):339-44. PubMed ID: 23289847 [TBL] [Abstract][Full Text] [Related]
40. Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution. Garg P; Mathur U; Sony P; Tandon R; Morris TW; Comstock TL Asia Pac J Ophthalmol (Phila); 2015; 4(3):140-5. PubMed ID: 26065499 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]